PRGF-Endoret

Endoret® Technology

What is it?

Endoret®  is a Biomedical Technology aimed at stimulating tissue regeneration by applying autologous proteins.

  • Hundreds of endogenous proteins affect the tissue repair processes, including angiogenesis, chemotaxis and cell proliferation. No exogenic agent can effectively govern all these processes.

  • ENDORET® technology provides the means necessary for the isolation and concentration of the blood proteins involved in tissue regeneration, as well as its suitable application at the injury site. 

Active Substances

Growth Factors

ENDORET® stimulates tissue regeneration due to its content in growth factors, in greater concentrations than those of blood.

 

Fibrin Membrane

Enables the balanced and gradual release of a large number of molecules, including growth factors and other proteins.

Therapeutic Formulations

With ENDORET® technology we can make 4 different therapeutic formulations
and adapt them to the different clinical goals. 

Mechanisms of Action
  1.  Promoting angiogenesis 

  2.  Stimulating cell migration 

  3.  Increasing the proliferation

  4.  Decreasing inflammation and pain

  5.  Stimulating autocrine and paracrine secretion of growth factors

                            

Safety

100% Autologous product, there are no incompatibilities nor risk of rejection.

All the formulations of ENDORET® have a bacteriostatic effect, especially during the 4 hours after application.

More than 700,000 patients have been treated in more than 20 countries, without any adverse effects being reported.

 

Applications of Endoret Technology® in Implantology

Increased PredictabIlIty

The use of Endoret® significantly increases the  success rate in treatments with dental implants.

When the surface of the implants is wetted with ENDORET® liquid a fibrin membrane is formed that adheres to the surface of the implant and releases growth factors and improves the osseointegration. The nano-rough surface of BTI implants is specially designed to boost the biological effects of ENDORET®.

Wetting with Endoret® increased the trabecular thickness and maturity of the bone.

Survival rates reported in  prospective trials:

  • 5-year follow-up study

            5787 implants. 99.2% (16)

  •  5-year follow-up study 

            1139 immediate load implants.99.3% (17)

  •  8-year follow-up study 

            1287 short implants. 99.3% (18)

  •  10-12-year follow-up study 

             111 short implants. 98.9% (19)

 

Endoret® in the Treatment of Bronj

ENDORET was effective in the surgical treatment of bisphosphonate-associated osteonecrosis of the jaw, achieving closure of the defect in 32 patients in a prospective study.
Endoret restored the function of the inferior dental nerve affected by the BRONJ
lesion. 

Treatment of Post-extraction Sockets

The application of ENDORET® in the treatment of post-extraction sockets reduces inflammation and pain, accelerates the epithelization of soft tissues and promotes
bone regeneration.

The survival rate of an implant placed in an alveolus post-extraction immediately is 98%, and is a safe, effective and predictable treatment.

Preparation of Grafts

ENDORET® can be used to agglutinate biomaterial, making it easier to handle and
improving its osteoconductive and biological properties, in both heterologous and
autologous grafts. 

Treatment of Maxillar Atrophy

Lateral Bone Increase

ENDORET® improves tissue regeneration, and because of its versatility, it can be used in various surgical techniques.

The crestal expansion and crestal split techniques in two stages combined with ENDORET® treatment can achieve an average bone expansion of 3.35 mm.

The use of ENDORET®, in combination with the block graft, improves the healing of the flap, avoids exposure of the graft, and improves the post-operative outlook of the patient.

Sinus Elevation

ENDORET® reduces inflammation and pain. It
increases the bone formed and maintains the survival of the bone cells.

ENDORET® is effective in the treatment of perforations in the Schneider membrane.

Endoret® increases the  revascularization of the bone graft  and the formation of mature bone

Vertical Bone Regeneration

The combination of ENDORET® treatment with short and extra-short implants makes
restorations in atrophic crests possible without needing to resort to more aggressive techniques.

Periodontal Regeneration

ENDORET® may be an alternative to the use of dermal material used in the field of mucogingival surgery.

ENDORET® achieves favorable results in terms of radicular cover and gain in clinical insertion. In addition, it increases the width of keratinized tissue and corrects recession.

Reduced Risk of Osteonecrosis

Treatment with ENDORET® after resecting the necrotic bone increases the activity of the osteoclasts and causes angiogenesis, which can be used as an adjuvant for patients with BRONJ. 
The results of various studies suggest that treatment with ENDORET® can lessen the risk of developing bROnJ after a dental extraction in high-risk patients in treatment with bisphosphonates.

 

Treatment

 

Number of extractions

 

Osteonecrosis of the maxilla

Control

267

5

Endoret® (PRGF®)

542

0

Components of Endoret Technology®

Endoret® Equipment*

Start Equipment
  • BTI ENDORET® Centrifuge

  • Plasmaterm H Warming Oven

  • Work rack

  • Activation glass bowls

The application of Endoret technology complies with all the regulations required By the Spanish Agency of Medicines and Medical Devices, Food and Drug Administration Agency (FDA) and European Union. For European union our medical devices are identified with CE mark.

Endoret® Training

Exclusive training adapted to medical needs. we share our new clinical research and provide training for innovative, top-quality healthcare.

Endoret® Disposable Kit Single-Use Kit*

KMU15 - US Kit
  •  6 Blood Extraction Tubes

  •  4 Fractioning Tubes

  •  1 Activation Syringe

  •  1 Plasma Transfer Device (PTD2)

  •  1 Winged Blood Collection Set

  •  5 Identification Labels

  •  1 Latex-Free Tourniquet

  •  1 Single Use Activator

Endoret® Certification

We certify the clinical qualification and experience of our customers with our training certificates.

Advantages of Endoret Technology®

ENDORET® technology is the market leader in the development of specific protocols for tissue regeneration, a pioneering technology manufactured exclusively by BTI Biotechnology Institute.

  • Optimum concentration of platelets

            The right concentration of platelets affects the final efficacy.

  • Formulation free of leukocytes

            The inclusion of leukocytes increases pain and inflammation and accelerates the deterioration of the fibrin.

  • Controlled activation

           Enables the formation of the fibrin matrix in situ and the gradual release of growth factors, maintaining its efficacy over time. 

  • Autologous

            It is made from the patient's own blood, so there are no known adverse effects.

  • Reproducible

            The protocol for the preparation process and its clinical application is strictly defined and tested.

  • Versatile

           4 therapeutic formulations obtained in the same process means we can adapt the product to the patient's clinical needs.

Safety and Regulatory Assurance

The application of Endoret® technology complies with all the regulations required by the Spanish Agency of Medicines and Medical Devices, Food and Drug Administration Agency (FDA) and European Union.

Quality Assurance
  • The ENDORET® closed-technique system complies with the highest standards of quality.

  • Both the system and the materials have the CE health certificate awarded by TÜV for specific application to oral surgery.

Guarantees of Efficacy
  • BTI has the greatest clinical support in the world published in this field; its effectiveness is proven in more than 100 international scientific publications.
Additional  Guarantees
  • BTI certifies its customers' specific training in the use of this technology.

  • In addition, BTI guarantees the traceability of its materials, and helps transfer all necessary information to its patients.